We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Convatec Group Plc | LSE:CTEC | London | Ordinary Share | GB00BD3VFW73 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.60 | -5.66% | 260.00 | 259.80 | 260.20 | 268.40 | 255.80 | 267.80 | 8,687,455 | 15:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 2.14B | 130.3M | 0.0636 | 40.94 | 5.34B |
From Apr 2019 to Apr 2024
By Michael Dabaie
Medtronic PLC (MDT) said it received investigational approval from the U.S. Food and Drug Administration to proceed with a pivotal trial for a new extended wear infusion set.
The goal of the study will be to collect clinical data to support the use of the extended wear infusion set for up to seven days--more than twice the length of time that any infusion set can currently be used. The study will enroll up to 150 subjects, aged 18 to 80, with type 1 diabetes on insulin pump therapy.
Infusion sets allow people on insulin pump therapy to deliver insulin under the skin to maintain healthy blood glucose levels. Current generation infusion sets must be changed every two to three days, Medtronic said.
Developed with ConvaTec's Unomedical subsidiary, this new infusion set aims to extend patient wear time by using new adhesive technology as well as maintaining insulin stability, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 16, 2019 09:43 ET (13:43 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Convatec Chart |
1 Month Convatec Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
